A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients by Feliubadaló, Lidia & Molina Pineda Infantas, Ignacio Jesús
A Collaborative Effort to Define Classification Criteria
for ATM Variants in Hereditary Cancer Patients
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BACKGROUND: Gene panel testing by massive parallel
sequencing has increased the diagnostic yield but also
the number of variants of uncertain significance.
Clinical interpretation of genomic data requires exper-
tise for each gene and disease. Heterozygous ATM path-
ogenic variants increase the risk of cancer, particularly
breast cancer. For this reason, ATM is included in most
hereditary cancer panels. It is a large gene, showing a
high number of variants, most of them of uncertain
significance. Hence, we initiated a collaborative effort to
improve and standardize variant classification for the
ATM gene.
METHODS: Six independent laboratories collected infor-
mation from 766 ATM variant carriers harboring 283
different variants. Data were submitted in a consensus
template form, variant nomenclature and clinical infor-
mation were curated, and monthly team conferences
were established to review and adapt American College
of Medical Genetics and Genomics/Association for
Molecular Pathology (ACMG/AMP) criteria to ATM,
which were used to classify 50 representative variants.
RESULTS: Amid 283 different variants, 99 appeared
more than once, 35 had differences in classification
among laboratories. Refinement of ACMG/AMP crite-
ria to ATM involved specification for twenty-one
criteria and adjustment of strength for fourteen others.
Afterwards, 50 variants carried by 254 index cases were
classified with the established framework resulting in a
consensus classification for all of them and a reduction
in the number of variants of uncertain significance from
58% to 42%.
CONCLUSIONS: Our results highlight the relevance of
data sharing and data curation by multidisciplinary
experts to achieve improved variant classification that
will eventually improve clinical management.
Introduction
Genetic diagnosis for hereditary cancers (HC) has
changed over the past decade thanks to the introduction
of massive parallel sequencing (MPS) technologies
which allow the screening of multiple genes outright.
MPS diagnostic panels increase sensitivity but also the
number of variants of uncertain clinical significance
(VUS) identified; application of MPS panels poses a sig-
nificant challenge in the clinical management of patients
and evidences the need for standardization in variant
classification. The American College of Medical
Genetics and Genomics (ACMG) and the Association
for Molecular Pathology (AMP) have provided a general
framework for classification of genetic variants (1).
However, these universal guidelines need to be tuned
according to the disease and the specific gene by a con-
sensus of experts. Currently ACMG/AMP guidelines
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have been adapted for some hereditary cancer genes
such as PTEN (2), CDH1 (3), and TP53 (4).
Most of the currently used HC panels include
the ATM gene, mainly because heterozygous ATM
mutations increase the risk of cancer, particularly breast
cancer (BC) (5), and have also been associated with
colorectal, prostate, and pancreatic cancer predisposition
(6–8). A moderate breast cancer risk of about 2.4-fold
was estimated from breast cancer families with ATM
pathogenic variants (9). In this sense, ATM loss-of-
function variants confer an increase in breast cancer risk
10 times greater than that of missense variants (10);
however, the p.(Val2424Gly) missense variant seems to
confer a higher risk, comparable to that of BRCA2 var-
iants (11). For other cancers, an overall risk of 2.23
(94% CI 1.26–4.28) has been suggested to increase to
4.94 (95% CI ¼ 1.90 to 12.9) in carriers under 50 years
of age (8).
ATM is also responsible for the autosomal recessive
genetic disorder ataxia telangiectasia (AT) (MIM#
208900) (12). AT is a pleiotropic neurodegenerative
disease whose symptoms include malignancy and ge-
nome instability, often accompanied by immunodefi-
ciencies, premature aging, insulin resistance, and
infertility (13, 14). Most AT patients bear compound
heterozygous pathogenic variants from over 800 cur-
rently registered in the Human Genome Mutation
Database (15). A recent study in Spanish AT patients
identified disease-causing mutations in 96% of the
alleles studied, frameshift being the most common type
of variant (16). The ATM protein is a member of the
phosphatidyl inositol-3’ kinase-related protein kinase
(PIKK) family, which phosphorylates hundreds of tar-
gets containing Ser/Thr-Gln motifs, and plays critical
roles in double-strand break (DSB) DNA repair and cell
cycle (14). DNA breaks recruit inactive ATM dimers
through the Mre11-Rad50-NBS1 (MRN) sensor
complex, which allows ATM dissociation into Ser1981-
autophosphorylated active monomers, able to act upon
a number of direct substrates such as TP53 or indirect
such as histone H2AX (14). These events are key indica-
tors of ATM functional activity, and coordinated activ-
ity of phosphorylated downstream targets determines
whether the genomic instability resulting from DNA
damage can be prevented (17).
With the aim of improving and standardizing vari-
ant classification for HC genes in Spain, 6 independent
molecular laboratories using MPS panels agreed to
create a common variant database. ATM was chosen for
the pilot study because it is a large gene included in the
majority of HC panels and shows a remarkable number
of VUS (18). After adapting ACMG/AMP classification
guidelines to ATM, 50 variants were designated for
classification with the established consensus.
Materials and Methods
A detailed description of the methodology used can be
found in the Supplemental Patients and Methods.
Briefly, a multidisciplinary group was built with com-
plementary expertise. Most of the members are molecu-
lar geneticists with experience in hereditary cancer and
RNA splicing. Some are members of gene-specific inter-
national endeavors such as Evidence-based Network for
theInterpretation of Germline Mutant Alleles
(ENIGMA, https://enigmaconsortium.org/),
International Society for Gastrointestinal Hereditary
Tumours (InSiGHT, https://www.insight-group.org/),
and Clinical Genome Resource (ClinGen, https://clini-
calgenome.org/). In addition, the team had a Spanish
expert in AT and ATM functional assays and 2 experts
in computational biology and bioinformatics. Patients
included in this study were seen in the different genetic
counseling units of each reference laboratory. All
patients had a clinical suspicion of HC and were tested
by gene panel sequencing. All variants detected in the
ATM coding sequence and 20-bp surrounding regions
with minor allele frequency lower than 1% were col-
lected in the Spanish Hereditary Cancer Variant
Database (DB hereinafter) created for this purpose.
Cut-offs for allele frequency calculations, as well as
the selection of different splicing and protein prediction
assessment tools and the adjustment of the correspond-
ing threshold values, are described in the Supplemental
Methods. This section also details the process of func-
tional study type selection and the strategy for variant
classification of 50 pilot variants from our DB.
Results
ATM VARIANT DATABASE
In total, we collected information from 769 individuals
carrying 283 different ATM variants; 104 index cases
carried more than one ATM variant. Hereditary breast
and/or ovarian cancer was the most common clinical in-
dication in the whole cohort (67%) (Supplemental Fig.
1), being women 85% of individuals (Supplemental
Table 1). Ninety-nine of the 283 different variants col-
lected appeared in more than one family; 78 were found
in more than one laboratory, and 20 appeared in 10 or
more families (Supplemental Fig. 1). The 5-tier patho-
genicity classification given by each laboratory was
recorded, and 35 of the 78 variants detected by more
than one laboratory had discordant classifications
(45%). Thirty of these discordances were due to the var-
iant being classified as VUS vs. likely benign (LB); the
remaining 5 discordances were as follows: 3 from likely
pathogenic (LP) vs. pathogenic (P), 1 from VUS vs. be-
nign (B), and 1 from VUS vs. LP.
Classification of ATM Variants
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ATM-SPECIFIC REFINEMENT OF ACMG-AMP CLASSIFICATION
GUIDELINES
Based on previous studies of other HC genes (2, 3), we
decided to adapt the widely used ACMG/AMP classifi-
cation guidelines (1) to the characteristics of the ATM
gene and its associated phenotypes. From the 28 criteria
listed in the guidelines, several have been modified, re-
stricted, rejected as non-applicable or expanded to di-
verse strengths. The resulting criteria proposed are
detailed in Table 1. Criteria where modifications were
based on ATM-specific data and unpublished modifica-
tions are justified in the following sections. Some criteria
are not applied because they overlap with others (PP4),
ClinGen itself has discarded them (PP5 and BP6) (22)
or are not applicable to ATM (PP2, BP1, BP3 BP5, see
Table 1 footnotes). Combination rules are kept from
Richards et al. (1).
POPULATION EVIDENCE
Since allelic frequencies in general populations are power-
ful tools for identifying common benign variants, we used
the statistical framework defined by Whiffin et al. (23) to
calculate the maximum credible population allele fre-
quency (MCPAF) for ATM pathogenic variants with AT
data. We obtained a cut-off allele frequency in the general
population of 0.005 for BA1 and 0.0005 for BS1. We
translated the threshold to population datasets as the
lower boundary of their 99% confidence interval and pro-
pose to use any of the nonfounder GnomAD v2.1.1 non-
cancer populations (24). Due to the low penetrance of
ATM pathogenic variants for breast cancer, we cannot ap-
ply BS2 to healthy heterozygous variant carriers. BS2 is
met if we find one homozygous carrier without AT affec-
tation. BS2_Supporting will be applied to 2 homozygous
observations with no clinical data provided. As the main
manifestations of AT are neurologic, we propose to use
the GnomAD v2.1.1 non-neuro dataset.
PREDICTIVE EVIDENCE
Regarding splicing alterations, our performance assess-
ment of in silico predictors supports the election of the
predictor SPiCE (25) for variants affecting the canonical
donor splice site, applying PP3 when they exceed the
threshold of 0.240 (100% sensitivity), and BP4 when
they are below it (with a sensitivity of 89.9% to identify
variants not affecting splicing). For variants affecting the
canonical acceptor splice site, PP3 is assigned when ex-
ceeding the threshold of 0.789 (sensitivity 87.6%) and
BP4 when they are under 0.282 (with a sensitivity of
86.3% to identify variants not affecting splicing), no ev-
idence is considered for acceptor variants with scores be-
tween 0.282 and 0.789. No called variants account for
6.2% of splicing altering and 10.8% of splicing neutral
variants in our dataset (Supplemental Fig. 2). For
activation or creation of splicing sites, we used a combi-
nation of predictors such as SpliceSiteFinder-like,
MaxEntScan and GeneSplicer, as detailed in Table 1.
In relation to protein predictors for missense var-
iants, we performed a comparative analysis of different
tools for the two ATM halves (see Supplemental
Methods and Supplemental Table 2). Our results sus-
tain the use of the following combinations of two pre-
dictors: REVEL plus VEST4 for the N-terminal half
(residues 1–1959) and REVEL plus PROVEAN for the
C-terminal half (residues 1960–3056). We proposed
the same procedure for both halves: PP3 or BP4 is
awarded when the 2 predictors assigned to the protein
half agree on a damaging effect or an absence of effect,
respectively; otherwise, the contribution of in silico evi-
dence is not considered.
FUNCTIONAL EVIDENCE
Spliceogenic variants are usually confirmed by the study
of the RNA of carriers or by mini-gene assays. Splicing
analysis in RNA from a carrier, if well designed and per-
formed quantitatively with the appropriate controls, can
demonstrate that a variant produces only aberrant tran-
scripts with premature termination codons undergoing
nonsense-mediated decay (NMD). We consider that such
cases deserve to be very strong pathogenic evidence,
PS3_VeryStrong, analogous to the strength bestowed in
ClinGen’s PVS1 decision tree (19). We propose a gradual
decrease of PS3 strength when the damaging effect is less
certain or less severe (Tables 1 and 2).
Protein function assays are quite specific to the
gene and associated conditions. AT-patient cells show
hypersensitivity to ionizing radiation and other DSB-
DNA-inducing agents manifesting as absence of ATM
serine 1981 phosphorylation (26), decrease in cell sur-
vival, an increased rate of chromosomal aberrations and
defects in cell cycle checkpoints (14, 27, 28). Null var-
iants that result in the absence or loss of ATM expres-
sion or prevent the Ser1981-mediated activation of
ATM, reduce the phosphorylation of numerous sub-
strates and increase the sensitivity to DNA damaging
agents have been associated with classical AT pheno-
types. On the other hand, missense and splicing var-
iants allowing some ATM expression, thus presenting
residual kinase activity and/or intermediate sensitivity
to agents that damage DNA, have been associated with
AT patients with milder or atypical phenotypes (16,
29). Consequently, we consider that these 3 functional
assays are useful for investigating the pathogenicity of
ATM variants for the 2 phenotypes (Fig. 1, A). We
propose to confer different strengths to PS3 depending
on how many of the 3 assays are found to be altered,
and the extent of the alteration. Thereby, PS3 will be
met when the 3 assays are completely altered,
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Table 1. ATM variant classification proposed criteria.
PATHOGENIC CRITERIA
Criteria Criteria description Specification
STAND-ALONE CRITERION
PVS1_StandAlone For a full gene deletion, a pathogenic classification is warranted (in the
absence of conflicting data).a
None
VERY-STRONG CRITERIA
PVS1 -Null variant (nonsense, frameshift, canonical 61 or 2 splice sites, single
or multi-exon deletion or tandem duplication) predicted to undergo
NMD.a OR





AT patients with de novo score 4.0 as per ClinGen SVI
Recommendation for de novo Criteria (PS2 & PM6) - Version 1.0.c
Strength
PS3_VeryStrong Splicing analysis in RNA from a carrier quantitatively proves that the vari-
ant produces a splicing alteration predicted to undergo NMD, and the
variant allele does not produce any full-length transcript. See text and
Table 2 for details.
Strength
PS4_VeryStrong Sixteen AT families.d
It can only be applied to AT families and NOT in: breast cancer families,
breast cancer case-control studies, variants that meet BA1 or BS1, nor
together with PM3 at any strength.
Strength
PM3_VeryStrong AT probands with in trans score 4.0 as per ClinGen SVI
Recommendation for in trans Criterion (PM3) - Version 1.0.e It cannot




PS1 Same amino acid change as a previously established pathogenic variant





AT patients with a de novo score 2.0-3.75 as per ClinGen SVI
Recommendation for de novo Criteria (PS2 & PM6) - Version 1.0.c
Strength
PS3 -SPLICING analysis in carrier RNA quantitatively proves that:
 the variant alters splicing resulting in a deletion or insertion NOT pre-
dicted to undergo NMD but to alter/truncate a region critical to pro-
tein function or remove >10% of protein, and the variant allele does
not produce any full-length transcript. See text and Table 2 for details.
OR
- The three following PROTEIN studies performed in AT patients or trans-
fected cells show a strong alteration:
 levels of ATM protein (or ATM phosphorylated in Ser1981)
 levels of phosphorylation of two ATM substrates
 sensitivity to DNA damaging agents. See text and Fig. 1 for details.
ATM-specific
PS4 Four to 15 AT probands.d
It can only be applied to AT families and NOT in: breast cancer families,
breast cancer case-control studies, variants that meet BA1 or BS1, nor
together with PM3 at any strength.
Strength
PVS1_Strong -Nonsense, frameshift, canonical 61 or 2 splice sites, single or multi-exon
deletion NOT predicted to undergo NMD but to alter/truncate a region
critical to protein function or remove >10% of protein.a
-Also single or multi-exon duplication presumed in tandem with
prediction of NMD.a
None
PM3_Strong AT probands with in trans score 2.0-3.75 as per ClinGen SVI
Recommendation for in trans Criterion (PM3) - Version 1.0.e It cannot
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Table 1. (continued)
PATHOGENIC CRITERIA
Criteria Criteria description Specification
PP1_Strong Co-segregation with AT in multiple affected family members, with 7
meioses observed across at least two families.d,f
Strength
MODERATE CRITERIA
PM1 Variant affecting the mutational hotspot codon p. R3008 (NP_000042.3;
see Results section) or the autophosphorylation codon p. S1981. See
text for reasoning.
ATM-specific
PM2 Absent, or present at<0.00001 (0.001%) allele frequency in gnomAD or
another large sequenced population. If multiple alleles are present
within any subpopulation, allele frequency in that subpopulation must
be<0.00002 (0.002%).f
ATM-specific
PM3 AT probands with in trans score 1.0–1.75 as per ClinGen SVI
Recommendation for in trans Criterion (PM3) - Version 1.0.e It cannot
be applied to variants that meet BA1 or BS1, nor together with PS4 at
any strength.
Strength
PM4 Protein length changes as a result of in-frame deletions/insertions
impacting at least one residue in a critical functional region (see PM1)
ATM-specific
PM5 Missense change at an amino acid residue where a different missense
change determined to be pathogenic or likely pathogenic has been
seen before. In addition, variant being interrogated must have a




AT patients with de novo score 1.0–1.75 as per ClinGen SVI
Recommendation for de novo Criteria (PS2 & PM6) - Version 1.0.c
Strength
PVS1_Moderate Nonsense, frameshift, canonical 61 or 2 splice sites, single or multi-exon
deletion NEITHER predicted to result in NMD NOR to alter/truncate a
region critical to protein function, removing <10% of protein.a
None
PS3_Moderate - SPLICING analysis:
 in patient RNA quantitatively proves that the variant alters splicing result-
ing in a deletion or insertion NOT predicted to result in NMD but to re-
move <10% of protein, and the variant allele does not produce any
full-length transcript; OR
 in patient RNA quantitatively proves that the variant produces 90%–99%
of altered transcript predicted to undergo NMD; OR
 with a mini-gene quantitatively proves that the variant alters splicing
resulting in NMD, and the variant allele does not produce any full-
length transcript; OR
 in patient RNA with NMD inhibition, semi-quantitatively shows with simi-
lar band intensity that the variant alters splicing resulting in NMD, with-
out evidence that the variant allele produces any full-length transcript.
See text and Table 2 for details.
OR
-Two of the following PROTEIN studies in AT patients or transfected cells
show a strong alteration and the other one shows an intermediate al-
teration or has not been performed:
 levels of ATM protein (or ATM phosphorylated in Ser1981)
 levels of phosphorylation of two ATM substrates




PS4_Moderate Two to three AT probands.d
It can only be applied to AT families and NOT in: breast cancer families,
breast cancer case-control studies, variants that meet BA1 or BS1, nor
together with PM3 at any strength.
Strength
Continued
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Table 1. (continued)
PATHOGENIC CRITERIA
Criteria Criteria description Specification




PP1 Co-segregation with AT in multiple affected family members, with 3–4
meioses observed.d,f
ATM-specific
PP2 Missense variant in a gene that has a low rate of benign missense varia-
tion and in which missense variants are a common mechanism of
disease.
N/Ah
PP3 -Probability of splicing alteration of the closest natural site predicted with
SPiCE 2.1 is  0.240 for donor sites or  0.789 for acceptor sites, OR a
splicing site is created/activated according to at least 2 splicing predic-
tors of the set SpliceSiteFinderlike-MaxEntScan-NNSplice, with a score
higher than the score of the natural site in the mutated allele.i OR
-Only for missense variants, when the above splicing predictors indicate
no impact, but protein predictors do. For variants affecting codons
1–1959, PP3 is met when VEST4 and REVEL predict damaging effects
(scores >0.5). For variants affecting codons 1960–3056, PP3 is met
when PROVEAN (score <-2.5) and REVEL (score >0.5) predict damag-
ing effects.j
ATM-specific




PP5 Reputable source recently reports variant as pathogenic, but the evidence
is not available to the laboratory to perform an independent evaluation.
N/Ak
PS1_Supporting Different variant at same nucleotide position as a pathogenic SPLICING
variant, where in silico models predict impact equal to or greater than





AT patients with de novo score 0.5-0.75 as per ClinGen SVI
Recommendation for de novo Criteria (PS2 & PM6) - Version 1.0.c
ATM-specific
PS3_Supporting - SPLICING analysis:
 with NMD inhibition in carrier RNA shows by visual inspection that the
altered and wild-type electrophoretic bands have similar intensity, and
the altered transcript is predicted to undergo NMD;
OR
 found in peer-reviewed article(s), without gel shown or quantitation
mentioned, where authors declare that the variant produces a
splicing alteration predicted to undergo NMD. See text and Table 2
for details.
OR
-One of the following PROTEIN studies in AT patients or transfected cells
shows a strong alteration and the other two show an intermediate
alteration or have not been performed:
 levels of ATM protein (or ATM phosphorylated in Ser1981)
 levels of phosphorylation of two ATM substrates




PS4_Supporting One AT proband.d
It can only be applied to AT families and NOT in: breast cancer families,
breast cancer case-control studies, variants that meet BA1 or BS1, nor
together with PM3 at any strength.
ATM-specific
PM1_supporting Missense or small in-frame deletion or insertion located in the kinase
(residues 2712–2962) or FATC (residues 3024–3056) functional
domains (NP_000042.3; see results section).
ATM-specific
PM3_Supporting AT probands with in trans score 0.5–0.75 as per ClinGen SVI
Recommendation for in trans Criterion (PM3) - Version 1.0.e It cannot
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Table 1. (continued)
PATHOGENIC CRITERIA
Criteria Criteria description Specification
BENIGN CRITERIA
Criteria Criteria description Specification
STAND-ALONE CRITERION
BA1 99% confidence interval of the variant allele frequency in any of the NFE,
AFR, LAT, EAS, SAS GnomAD v2.1 (non-cancer) populations is > 0.5%.l
ATM-specific
STRONG CRITERIA
BS1 99% confidence interval of the variant allele frequency in any of the NFE,
AFR, LAT, EAS, SAS GnomAD v2.1 (non-cancer) populations is >
0.05%).l
ATM-specific
BS2 Observed in the homozygous state in a healthy or AT-unaffected individ-
ual. One observation if homozygous status confirmed; two if not
confirmed.
Note that if BS1 is applied, BS2 must be downgraded to
BS2_Supporting.f
ATM-specific
BS3 - SPLICING analysis in carrier RNA demonstrate (by Sanger sequencing or
a quantitative technique) biallelic expression of the full-length
transcript by an exonic SNV. See text and Table 2 for details.
OR
-In a variant not predicted or proven to alter RNA splicing, the three fol-
lowing PROTEIN studies in AT patients or transfected cells show results
similar to a wild-type control:
 levels of ATM protein phosphorylated in Ser1981
 levels of phosphorylation of 2ATM substrates
 sensitivity to DNA damaging agents. See text and Fig. 1 for details.
ATM-specific
BS4 Lack of segregation in affected members of 2 or more AT families.f None
SUPPORTING CRITERIA
BP1 Missense variant in a gene for which primarily truncating variants are
known to cause disease.
N/Ah
BP2 Co-occurrence in trans of the variant with a pathogenic or likely patho-
genic ATM variant in well phenotyped AT-unaffected individual from
internal cohort or the literature.
ATM-specific
BP3 In-frame deletions/insertions in a repetitive region without a known
function
N/Am
BP4 -For synonymous and intronic variants, probability of splicing alteration of
the closest natural site predicted with SPiCE 2.1 is < 0.240 for donor
sites or < 0.282 for acceptor sites, AND no splicing site is created/
activated according to at least 2 splicing predictors of the set
SpliceSiteFinderlike-MaxEntScan-NNSplice (if a site is recognized, the
score is lower than the score of the natural site in the variant allele).i
-For coding non-synonymous variants, NEITHER splicing predictors as
above NOR protein predictors predict any impact. The latter is estab-
lished for variants affecting codons 1––1959 when both VEST4 and
REVEL (scores <0.5) predict NO alteration, and for variants affecting
codons 1960–3056 when both PROVEAN (score >-2.5) and REVEL
(score <0.5) predict NO alteration.j
ATM-specific
BP5 Variant found in a case with an alternate molecular basis for disease. N/An
BP6 Reputable source recently reports variant as benign, but the evidence is
not available to the laboratory to perform an independent evaluation.
N/Ak
BP7 Synonymous variant where nucleotide is not highly conserved (100
vertebrates basewise conservation PhyloP score < 6.66, available at
the UCSC Browser).o
This evidence can be used with BP4, as appropriate, to classify variants
meeting both criteria as likely benign.
ATM-specific
Continued
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PS3_Moderate when 2 are altered and 1 has not been
performed or gives intermediate results, and
PS3_Supporting when 1 is altered and the other 2
have not been performed or give intermediate results,
as depicted in Fig. 1, B.
In cases where experimental data from RNA and
protein support the same damaging effect, the evidence
of higher strength will be used. When RNA data do not
support an effect in splicing, the protein data prevail to
reflect other defects in protein function.
Benign criterion BS3 has a similar approach
(Tables 1 and 2). If assay(s) in carrier RNA demonstrate
biallelic expression of the variant or an exonic single
nucleotide variation (SNV), quantitatively or with simi-
lar peak height by Sanger sequencing, BS3 will be met.
BS3_Supporting is achieved when no additional band
to wild-type is detected in electrophoresis of carrier
RNA, although biallelic expression cannot be demon-
strated by an exonic variant. BS3 can be achieved by
protein assays when the 3 assays yield the same results as
the wild-type control (Fig. 1, B). BS3_Supporting is
met when 2 assays give the same results as wild-type and
the other one gives intermediate results or has not been
performed.
We have found germline deleterious missense
variants in AT patients, located throughout the ATM
Table 1. (continued)
PATHOGENIC CRITERIA
Criteria Criteria description Specification
BS2_Supporting Two homozygous observations with no clinical data provided, or meets
criteria for BS2 but BS1 is also applied.f Observations without clinical
data provided can be retrieved from the GnomAD non-neuro dataset.
ATM-specific
BS3_Supporting - SPLICING analysis in carrier RNA with NMD inhibition and proper
controls, shows only the wild-type transcript although do not demon-
strate biallelic expression by an exonic SNV. See text and Table 2 for
details. OR
-In a variant not predicted or proven to alter RNA splicing, two of the fol-
lowing PROTEIN studies in AT patients or transfected cells show results
similar to a wild-type control and the other one shows an intermediate
alteration or has not been performed:
 levels of ATM protein phosphorylated in Ser1981
 levels of phosphorylation of two ATM substrates
 sensitivity to DNA damaging agents. See text and Fig. 1 for details.
ATM-specific
BS4_Supporting Lack of segregation in affected members of one AT family.f ATM-specific
NMD, nonsense-mediated decay; AT, ataxia-telangiectasia; N/A, Not applicable to ATM.
aFollowing Tayoun et al., decision tree (19, 20).
bInitiation codon variants have been shown to cause (classic or atypical) AT and absence of ATM kinase (21). Expression studies performed in these patients show a shorter
underexpressed protein probably starting at the next in-frame methionine at codon 94 (21).
cPoint-based system to determine the strength of de novo evidence based upon confirmed versus assumed status, phenotypic consistency and number of de novo observa-
tions, available at https://clinicalgenome.org/working-groups/sequence-variant-interpretation/ (20).
dApplied analogously to CDH1 ClinGen Specifications (3, 20).
ePoint-based system to determine the strength of homozygous and in trans observations based upon variant phasing and classification of the variant occurring on the other al-
lele, available at https://clinicalgenome.org/working-groups/sequence-variant-interpretation/.
fApplied analogously to PTEN ClinGen Specifications (2, 20).
gIf the other missense change is determined to be likely pathogenic, the variant being classified should not reach pathogenic classification.
hBoth missense and frameshift variants contribute with comparable frequency to ATM-related diseases.
iSplicing predictor assessment is detailed in the text. SPiCE 2.1 predictions can be found at https://sourceforge.net/projects/spicev2-1/#.
jProtein predictor assessment is detailed in the text. VEST4 predictions can be found at http://cravat.us/CRAVAT/, REVEL predictions at https://sites.google.com/site/jpopgen/
dbNSFP and PROVEAN predictions at http://provean.jcvi.org/genome_submit_2.php? species¼human.
kFollowing Biesecker et al., recommendations (20, 22).
lThe 99% confidence intervals can be calculated in the INVERSE AF tab of the website http://cardiodb.org/allelefrequencyapp/; see Materials and methods and Results sections
for details on cut-offs.
mA repetitive region without a known function has not been found in ATM.
nThe frequency of pathogenic variants in ATM and other breast cancer predisposing genes is high enough to allow such combinations and a lethal or strikingly stronger pheno-
type is not anticipated.
oThe 100 vertebrates basewise conservation PhyloP score can be seen as a graphic track at the UCSC Genome Browser (https://genome.ucsc.edu/), and the scores can be down-
loaded for each position.
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protein and a similar distribution was observed in breast,
pancreatic, and prostate tumors (Fig. 2, A and B). In
contrast, missense variants with a MAF  0.05%
(gnomAD 2.1 controls) are distributed throughout the
ATM regions except for phosphoinositide 3-kinase
(PI3K) and FRAP, ATM, TRRAP C-terminal (FATC)
domains (Fig. 2, A). The absence of germline frequent
variants in PI3K and FATC C-terminal domains sug-
gests their critical role. For this, we propose applying
PM1_supporting to variants located in these specific
domains. We have also found some candidate codons
for a PM1 hotspot, according to the ClinGen
Germline/Somatic Variant Curation Subcommittee
(30). Two ATM codons accumulate >10 somatic
missense occurrences in cancerhotspots.org (v2)
(Supplemental Fig. 3). Codon 337 has 31 observations
of p.(Arg337His) and 9 of p.(Arg337Cys); codon 3008
has 15 observations, distributed between
p.(Arg3008Cys), p.(Arg3008His), and p.(Arg3008Leu).
In GnomAD v2.1.1 (noncancer) variants c.1009C>T
p.(Arg337Cys) and c.1010G>A p.(Arg337His) have 26
and 20 counts, respectively, whereas only variants
c.9022C>T p.(Arg3008Cys) and c.9023G>A
p.(Arg3008His) have been detected, with 3 and 2
counts, respectively. For this reason, we only consider
codon 3008 as a hotspot. In addition, we propose
applying PM1 to codon p. Ser1981, since autophos-
phorylation of this residue has been found to be
Fig. 1. Detailed functional criteria PS3 and BS3 based on protein data. A) Description of the 3 types of studies that can be com-
bined. Regarding ATM expression and ATM autophosphorylation in p. Ser1981, if both are available the latter will prevail.
Studies must be performed i) by directed mutagenesis in ATM-null human cells or ii) for noncommon variants (not meeting
BS1), in AT-patient derived cell lines that are homozygous or compound heterozygous for the test variant, where the other vari-
ant is predicted to truncate the protein and undergo NMD). B) Description of the possible combinations of the 3 different study
types to reach the specified strength levels. Note that for benign evidence, only ATM autophosphorylated levels can be used.
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required for sustained retention of ATM at DSBs.
Furthermore, its directed mutagenesis affects the abil-
ity of ATM to phosphorylate its downstream targets
after DNA damage and correct the radiosensitivity of
an AT cell line (31).
DE NOVO, ALLELIC AND SEGREGATION EVIDENCE
De novo criteria (PS2, PM6) and allelic evidence PM3
are applied following the ClinGen SVI recommenda-
tions (32, 33); segregation criteria (PP1, BS4) are for-
mulated as in published guidelines (2) only for AT
families, whereas the benign allelic evidence BP2 has
been simplified (Table 1).
PILOT CLASSIFICATION OF 50 ATM VARIANTS
We performed a pilot classification of 50 ATM variants
from our database which were selected to represent the
variant type proportions of the whole set. The evidence
assigned to each variant, the data and publications on
which they are based and the resulting pathogenicity
classes are displayed in Table 3 and Supplemental
Table 3. All this information together with the clinical
information (Supplemental Table 4) will be submitted
to ClinVar database (34) to be made publicly available
to the whole community.
The pilot reclassification of 50 variants with the
adapted criteria allowed us to reassign 18 cases from
VUS to a more clinically meaningful class; of the
remaining cases, 4 were moved to class 3 and 28 were
left unchanged (Table 3, Supplemental Fig. 1). Of note,
establishing ATM-adjusted cut-offs for BA1 and BS1 fa-
vored the classification of several recurrent variants as
class 1 or 2. The BS2_supporting criterion, applied to
variants with at least 2 appearances in the GnomAD
non-neuro dataset in the homozygous state, supported
by the high penetrance and young age of onset observed
Fig. 2. Distribution of missense variants along the ATM protein. A) Germline variants. Pathogenic missense variants (in blue) in
A-T patients were obtained from the literature (reported as pathogenic in AT patients), LOVD and/or HGMD). Benign missense
variants (in green) were present with a MAF greater than 0.05% in the GnomAD v2.1.1 control database. B) Location of missense
variants identified in breast, pancreatic, and prostate tumors in the cBioportal database. The protein domains are based on infor-
mation from UniProt and Pfam databases. The figure has been built using the software ProteinPaint, available at https://protein-
paint.stjude.org/.
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Table 3. Result of the 50-variant pilot classification.






c.61A>G p.(Thr21Ala) 1 3 3 PM2þBP4
c.162T>C p.(Tyr54=) 9 2, 3 2 BS1þBP4þBP7
c.496þ4T>C p.? 3 3 2 BP4þBS3_P
c.609C>T p.(Asp203=) 14 2, 3 2 BS1þBP4þBP7
c.826A>G p.(Lys276Glu) 1 3 3 PM2
c.998C>T p.(Ser333Phe) 60 2, 3 2 BS1þBS2_P
c.1380G>C p.(Thr460=) 2 2, 3 2 BS1þBP4þBP7
c.1463G>A p.(Trp488*) 1 5 5 PVS1þPM2þPM3 þPS3_P
c.1564_1565del p.(Glu522Ilefs*43) 2 5 5 PVS1þPM3_VS
c.1810C>T p.(Pro604Ser) 48 2, 3 1 BA1 (þ BS1þBS2_P)
c.1899T>G p.(Cys633Trp) 1 3 3 PM2
c.2012T>A p.(Ile671Lys) 1 3 3 BP4
c.2250G>A p.(Lys750=) 1 4 5 PP3þPS3_M þ PM3_VS þ BP7
c.2362A>C p.(Ser788Arg) 1 2 1 BA1 (þ BS1þBS2_P)
c.2386A>C p.(Asn796His) 1 3 3 PM2þBP4
c.2839-2A>G p.? 1 4 4 PVS1þPM2
c.2921þ1G>A p.? 2 4, 5 5 PVS1þPM3_VS þ PS3_P
c.2921þ1G>T p.? 1 5 5 PVS1þPM2þPS1_P
c.3747-1G>C p.? 2 4, 5 5 PVS1þPS4_P þ PM2þPS3_M
c.3802del p.(Val1268*) 3 4, 5 5 PVS1þPM3_VS þ PS3
c.4060C>A p.(Pro1354Thr) 2 3 3 BP4
c.4110-9C>G p.? 1 3 3 PS3_P þ PM3_P þ PP3þPM2
c.4396C>G p.(Arg1466Gly) 4 3 3 PM2þPP3
c.4802G>A p.(Ser1601Asn) 2 2, 3 3 BP4
c.4852C>T p.(Arg1618*) 1 4 5 PVS1þPS4_M þ PM2
c.5071A>C p.(Ser1691Arg) 9 2, 3 1 BS1þBS2_P þ BS3
c.5373T>C p.(Asp1791=) 1 2 3 PM2þBP4þBP7
c.5558A>T p.(Asp1853Val) 32 2, 3 1 BA1 (þ BS1þBS2_P þ PP3)
c.5623C>T p.(Arg1875*) 2 5 5 PVS1þPM3_S þ PS3_M
c.6067G>A p.(Gly2023Arg) 19 2, 3 3 BS1þPP3
c.6115G>A p.(Glu2039Lys) 1 3 3 PS4_P þ PM2þPP3
c.6203T>C p.(Leu2068Ser) 1 3 4 PM2þPS4_M þ PS3_M þ PP3
c.6315G>C p.(Arg2105Ser) 1 3 3 PP3
c.6679C>T p.(Arg2227Cys) 1 4 5 PM2þPS4þPP3þPS3_M þ PP1
c.6848C>T p.(Ser2283Leu) 2 3 3 PM2þBP4
c.6860G>C p.(Gly2287Ala) 1 3 3 BP4
c.7135C>G p.(Leu2379Val) 1 4 3 PS3_M þ PP3
c.7191A>G p.(Gln2397=) 2 3 2 BP4þBP7
c.7375C>G p.(Arg2459Gly) 10 3 3 PP3
c.7381C>T p.(Arg2461Cys) 1 3 3 PP3
Continued
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in AT patients, allowed the classification of 5 variants as
likely benign by its combination with BS1, without any
other evidence needed. Similarly, our DB recorded the
appearance of 3 variants in homozygosis in well-
phenotyped individuals not presenting AT. This infor-
mation allowed us to classify variant c.998C>T as likely
benign; this variant was present in 60 patients in our
DB but did not reach BS2_P requirements with
GnomAD data.
Nineteen out of 50 variants of the pilot study were
classified as class 4 or 5 being present in 27 patients
from our Spanish cohort. Most of these patients had
breast/ovarian cancer although there were cases of other
tumors (Supplemental Table 5). Cosegregation data was
available in a few of these families and, as expected for
a moderate penetrance cancer risk gene, was not very
informative (Supplemental Table 5).
Discussion
Variant classification is one of the main clinical chal-
lenges in the MPS era, being an enormous bottle neck
in most genetic testing laboratories. In this article, we pre-
sent the seed for a Spanish database of hereditary cancer
variants, beginning with 6 laboratories and 1 gene, ATM.
We identified ATM as a good candidate since it is one of
the genes with more identified VUS (18) and it has been
associated with different cancer syndromes (6–8, 10), mak-
ing it well worth the joint effort to refine variant classifica-
tion. Since there were no specific criteria for ATM variant
classification, we also made an effort to adapt the ACMG/
AMP guidelines (1) to ATM.
In our pilot classification study, the use of ATM-
specific guidelines and data sharing amongst experts and
clinical laboratories led to a decrease in VUS from 58%
to 42%, with the identification of 27 carriers of ATM
(likely) pathogenic variants. Because pathogenic ATM
variants predispose to potentially lethal cancers for
which there are clinical management recommendations
(35), these findings are clearly clinically actionable for
carrier individuals and their relatives.
Since the ACMG/AMP classification guidelines were
proposed for high-penetrance genes in classical Mendelian
disorders (1), their adaptation to moderate/low-penetrance
genes, such as ATM, is challenging and requires collabora-
tive efforts. In this respect, we analyzed every ACMG/AMP
classification criterion in the context of reported knowledge
about the ATM gene, ATM protein function and ATM re-
lated phenotypes, with the aim of better adjusting each cri-
terion and eventually facilitating variant classification in
routine clinical laboratories. In this process, we took advan-
tage of the fact that biallelic ATM variant carriers present
the highly penetrant AT disease, allowing the use of criteria
for recessive phenotypes. Our adjusted cut-offs for popula-
tion variant frequency enabled the classification of a large
quantity of recurrent variants as (likely) benign that would
have been classified as VUS with the original general
ACMG/AMP thresholds (1). In this sense, although our
DB only contains variants below the common population
frequency cut-off of 1%, 39 out of 283 unique variants
meet the adjusted BS1 and 12 of these also meet the
adjusted BA1. The 39 BS1 variants account for 51% of the
individual entries in (448 out of 882, data not shown).
We found it especially challenging to establish func-
tional evidence for or against pathogenicity. At the protein
level, the selected assays were based on relevant functional
characteristics of ATM that are altered in AT patients and
are involved in oncogenic mechanisms, such as double-
Table 3. (continued)






c.7390T>C p.(Cys2464Arg) 1 3 3 BS1þPP3
c.7788þ3A>G p.? 1 4 4 PM2þPM3þPP3þ PS3_P
c.8122G>A p.(Asp2708Asn) 1 4 4 PM2þPP3þPS3_M þ PM3_S
c.8269-5T>G p.? 1 3 3 PM2
c.8734A>G p.(Arg2912Gly) 4 3 3 PP3þPM1_P
c.8786þ1G>T p.? 1 5 5 PVS1þPS3_M þ PM2
c.8876_8879del p.(Asp2959Glyfs*3) 2 5 5 PVS1þPS3_P þ PM3
c.9007_9034del p.(Asn3003Aspfs*6) 2 4 5 PVS1_S þ PS3þPM2þPM3
c.9023G>A p.(Arg3008His) 1 4 4 PM1þPM2þPS4_M
c.9079dup p.(Ser3027Lysfs*36) 1 4 4 PVS1_S þ PM2þPS4_M
See evidence details in Supplemental Table 3.
acode for evidence strength modifications: VS, Very Strong; S, Strong; M, Moderate; P, Supporting.
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strand break signaling (presence and activation of ATM,
phosphorylation of its substrates), and mitosis checkpoints
and chromosomal stability. We set the splicing-related cri-
teria at the RNA level on the basis of previous ENIGMA
and InSiGHT recommendations and the authors’ own ex-
perience. Additional considerations will be required if
ATM naturally occurring in-frame transcripts are described
that would rescue the variant allele effect. Functional evi-
dence has helped us to classify 18 out of 50 variants.
Luckily, splicing data from 5 of the 8 variants came from
our own laboratories. Unfortunately, protein functional
studies are not available in our teams. In this sense, the de-
velopment of calibrated high-throughput ATM functional
assays, similar to the saturation genome editing study pub-
lished for BRCA1 (36) will provide more power to PS3
and BS3 criteria.
The presence of a rare variant in AT families or in
trans with a (likely) pathogenic variant in an AT patient
has allowed us to classify 12 of 50 variants, while co-
segregation AT data has turned out to be scarce in the
literature. Conversely, ATM variant classification is
most frequently requested for breast cancer risk assess-
ment, but the great heterogeneity and numerous pheno-
copies of breast cancer impairs its use in co-segregation or
family counting evidence. Large case-control studies by in-
ternational hereditary cancer consortia like BRIDGES (37)
in Europe and CARRIERS (38) in US will hopefully help
to classify some of these variants.
An underlying assumption of this and other studies
in the field is that the very same spectrum of ATM
variants causing autosomal recessive AT disease when
present in both alleles, cause increased BC risk when
present in one allele. Overall, the assumption is proba-
bly true, and as far as we know, it holds true for
premature termination codon variants expected to cause
NMD. Nevertheless, some evidence suggests that subtle
differences might also exist. For instance, variant
p.(Val2424Gly) is associated with a 6-fold increased BC
risk, much higher than average truncating variants.
Conversely, the same variant does not cause classical
AT, but an attenuated form (11, 39). Another study
suggested that the risk of malignancies is higher in indi-
viduals with mild ATM missense variants producing
proteins with residual kinase activity (40).
In summary, by pooling variant information cur-
rently stored in individual clinical laboratories, we have
developed a general framework for homogeneous and
clinically useful variant interpretation in our country. It
will also serve for the identification of Spanish founder/
recurrent variants and analysis of their associated cancer
risk. Moreover, it will facilitate sharing of curated data
to international databases. In recent years, similar initia-
tives focused on the generation of clinical-grade genetic
variant databases have been conducted in other coun-
tries (41–44). In our case, we have started by adjusting
general ACMG/AMP guidelines to a single gene, ATM,
with the aim of using them within the framework of
molecular diagnostics for HC. In our joint effort we
performed a pilot study and classified 50 ATM variants
carried by 257 index cases. Our results highlight the rel-
evance of data sharing and data curation by multidisci-
plinary experts to achieve improved variant classification
that will eventually improve clinical management.
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Supplemental material is available at Clinical Chemistry
online.
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